Sprint Bioscience AB SPRINT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 3.65
- Day Range
- SEK 3.62–3.80
- 52-Week Range
- SEK 0.57–4.59
- Bid/Ask
- SEK 3.68 / SEK 3.75
- Shares Outstanding
- 105.52M
- Market Cap
- SEK 395.68M
- Volume/Avg
- 223,947 / 264,633
Key Statistics
- Price/Earnings (Normalized)
- 5.36
- Price/Sales
- 2.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 32
- Website
- https://www.sprintbioscience.com
Valuation
|
Metric
|
SPRINT
|
|---|---|
Price/Earnings (Normalized) | 5.36 |
Price/Book Value | 4.39 |
Price/Sales | 2.85 |
Price/Cash Flow | 5.16 |
Price/Earnings
SPRINT
Financial Strength
|
Metric
|
SPRINT
|
|---|---|
Quick Ratio | 7.09 |
Current Ratio | 7.09 |
Interest Coverage | 15.39 |
Quick Ratio
SPRINT
Profitability
|
Metric
|
SPRINT
|
|---|---|
Return on Assets (Normalized) | 90.07% |
Return on Equity (Normalized) | 112.61% |
Return on Invested Capital (Normalized) | 116.44% |
Return on Assets
SPRINT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|d#&fhF | LOCK|c&FK | $129B | |||
| Moderna Inc
MRNA
| LOCK|w>%$?## | LOCK|&Q@ | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#jwmdH | LOCK|v<>Z | $79B | |||
| argenx SE ADR
ARGX
| LOCK|xM?KJ$& | LOCK|<m | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<^HkS!% | LOCK|^J | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|BMz!&D | LOCK|kh>! | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>Sg#&%j> | LOCK|&%RCK | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|T@!G&B | LOCK|<C$ | $24B | |||
| Incyte Corp
INCY
| LOCK|g@@Kbp | LOCK|S@Y | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|rg@Q<% | LOCK|FK | $14B |
United States